Investor Presentation

January 11, 2016

Albert D. Friesen, PhDChair & CEO

Dawson ReimerPresident & COO

2

Disclaimer

This presentation is for informational purposes only and should not be considered as an offer

to buy or sell securities. No stock exchange has either approved or disapproved of the

information that is contained in this presentation. This presentation may contain

forward-looking statements within the meaning of Canadian Securities legislation and the

forward-looking statements contained herein are made as at the date of this presentation and,

accordingly, are subject to change after such date. Undue reliance should not be placed on

such statements. These statements involve a number of risks and uncertainties including

statements regarding the outlook for Medicure Inc., business and operational results. By

nature, these risks and uncertainties could cause actual results to differ materially from what

has been indicated. Factors that could cause actual results to differ materially from any

forward-looking statement include, but are not limited to, product recalls, competition from

similar products and other factors including those risks and uncertainties identified above,

and those contained in the Company’s most recent MD&A and Form 20F.

Medicure Inc. undertakes no obligation to update publicly or otherwise revise any

forward-looking information as a result of new information, future results or other

such factors which affect this information, except as required by law.

3

Aggrastat Prescribing Information

Indication: AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).

Dosage and Administration: High-Dose Bolus Regimen:

Administer intravenously 25 mcg/kg within 5 minutes and then 0.15 mcg/kg/min for up to 18 hours. In patients with CrCl ≤60 mL/min, use the full bolus and halve the maintenance infusion.

Contraindications: Known hypersensitivity to any component of AGGRASTAT; History of thrombocytopenia with prior exposure to AGGRASTAT; Active internal bleeding, or history of bleeding diathesis, major surgical procedure or severe physical trauma within previous month

Warnings and Precautions: AGGRASTAT can cause serious bleeding. If bleeding cannot be controlled discontinue AGGRASTAT; Thrombocytopenia: Discontinue AGGRASTAT and heparin

Adverse Reactions: Bleeding is the most commonly reported adverse reaction

4

Medicure Inc.

Core Competencies:

Unique, head-office based sales team One of the only hospital cardiology

pharma sales teams in the U.S.

A specialty pharmaceutical company focused on the development and commercialization of

therapeutics for the U.S. hospital market.

5

Net Revenue Growth: 2012 – 2015 (CDN)

ActualQ1-Q32015

-

5,000,000

10,000,000

15,000,000

20,000,000

25,000,000

2012 2013 2014 2015

$ Canadian

Unaudited*

Net revenue for the three and twelve month period ended December 31, 2015 are preliminary and are based on

the best information currently available and subject to the completion of the financial statements for the period.

6

EBITDA Growth: 2012 – 2015

ActualQ1-Q3 2015

(2,000,000)

(1,000,000)

-

1,000,000

2,000,000

3,000,000

4,000,000

5,000,000

2012 2013 2014 2015

Adjusted EBITDA*

The Company defines EBITDA as "earnings before interest, taxes, depreciation, amortization and other income or expense" and Adjusted EBITDA as "EBITDA adjusted

for non-cash and one-time items". The terms "EBITDA" and "Adjusted EBITDA", as it relates to the three and nine months ended September 30, 2015 and August 31,

2014 results prepared using International Financial Reporting Standards ("IFRS"), do not have any standardized meaning according to IFRS. It is therefore unlikely to be

comparable to similar measures presented by other companies.

$ Canadian

Q1 – Q3

Only

7

Acute cardiovascular hospital product

I.V. platelet inhibitor; binds the GP IIb/IIIa receptor

Indicated for Acute Coronary Syndrome (ACS)

41% reduction in death and MI in high-risk patients*

Oct 2013: FDA Approved High Dose Bolus

Patented until June 2023

Sept 2015: sNDA filed for STEMI label expansion

* PRISM PLUS Investigators, N Engl J Med. 1998:1488-1497.

8* Gross Sales before discounts. Source: Wolters Kluwer Health + 10% for non-reporting hospitals

Commercial Product: Aggrastat®

United States GP IIb/IIIa MarketUSD $274.5 million, July 2014 – June 2015

Launched by Merck in 1998

Is the #1 in class ex-USA

U.S. rights acquired by Medicure in 2006

Medicure obtained broader FDA

approval in October 2013

9

Co

mp

etitive

Po

sitio

nin

g o

f A

gg

rasta

t

10

Weekly Bag Demand (“Weekly Scripts”)

0

200

400

600

800

1000

1200

1400

1600

Rolling 3 Month Average Bag DemandB

ag

s / W

eek

Label

Change Oct 2013

11

$0

$500

$1,000

$1,500

$2,000

$2,500

$3,000

$3,500

12-hr Infusion (90 kg patient)

Required

Units:

Aggrastat: 25 µg/kg bolus + 0.15 µg/kg/min

Integrilin: 2x180 µg/kg bolus + 2.0 µg/kg/min

Reopro: 0.25 mg/kg bolus + 0.125 µg/kg/min

US $; Based on WAC pricing as of January 2015. Cost of heparin has not been included. Cost comparisons do not imply comparable efficacy, safety or product interchangeability. Aggrastat,

Reopro (abciximab), and Integrilin (eptifibatide) have not been compared in head-to-head clinical trials. Please refer to prescribing information for approved indications for all products.

US healthcare system is

financially stressed

Integrilin often one of the largest

pharmacy line items

Typical hospital savings:

$50,000 - $500,000 / year

GPI Treatment Costs in the US

$3,126.12Reopro

$1,435.78Integrilin

$517.81Aggrastat

12

Building a specialty

pharmaceutical portfolio focused

on the U.S. hospital market

Leveraging our sales

infrastructure

Invest in reduced risk - high

reward development projects

Maintain focus on profitability

Growth & Business Development

13

Apicore Transaction: July 2014

5.3%Equity

Equity investor Loan + Warrants

FoundersMinority Shareholder

Fixed Price OptionFixed Price Option

a private manufacturer of complex active pharmaceutical ingredients (APIs) and developer of generic products (ANDAs)

14

API Manufacturer & ANDA Developer

Complex synthetic chemistry

Early & “first to file” generics

Secure, high quality production

History:

Founded in 2004 (New Jersey)

First FDA approval in 2006 (Granisetron)

Expanded Indian facility in 2013-14

Total 200 employees

>80 Products

>50 Customers (Mylan, Teva, Sandoz, etc)

Year Revenue (USD)

2012 $5 Million

2013 $10.3 Million

2014 $14.3 Million

Apicore Background

Somerset, New Jersey

Vadodara, Gujarat, India

15

Key Financial Info – MPH: TSXV

*Removing non-cash stock-based compensation expense and one-time items (SNDA Filing) in the EBITDA

Cap Structure As of January 8, 2016

Basic Total 14,445,168

Fully Diluted Total 16,740,213

Share Price C$4.74

Market Cap C$68.5 M

Recent Financial Highlights

Q4 Net Revenue Est. $9.3 M

Q1-Q3 Net Revenue $12.6 M

Q1-Q3 *Adj.EBITDA $4.0 M

2016 Focus

Continue to grow Aggrastat revenue

Diversify through product & business development

16

Business Vision

To build a large, stable, specialty pharmaceutical company

To further expand Aggrastat revenue

To expand revenue with new commercial products

To diversify company value with new products and business areas

Aggrastat Quarterly Net Product Sales (CDN Millions)

-

1,000,000

2,000,000

3,000,000

4,000,000

5,000,000

6,000,000

7,000,000

8,000,000

9,000,000

10,000,000

Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4

2012 2013 2014 2015

17

Aggrastat Prescribing Information

Indication: AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).

Dosage and Administration: High-Dose Bolus Regimen:

Administer intravenously 25 mcg/kg within 5 minutes and then 0.15 mcg/kg/min for up to 18 hours. In patients with CrCl ≤60 mL/min, use the full bolus and halve the maintenance infusion.

Contraindications: Known hypersensitivity to any component of AGGRASTAT; History of thrombocytopenia with prior exposure to AGGRASTAT; Active internal bleeding, or history of bleeding diathesis, major surgical procedure or severe physical trauma within previous month

Warnings and Precautions: AGGRASTAT can cause serious bleeding. If bleeding cannot be controlled discontinue AGGRASTAT; Thrombocytopenia: Discontinue AGGRASTAT and heparin

Adverse Reactions: Bleeding is the most commonly reported adverse reaction

Thank you.Contact a Product Specialist

1.800.509.0544

For More Informationwww.medicure.com www.aggrastat.com

Investor Relationsir@medicure.com 1.888.435.2220 (Ext. 231)